The Asia-Pacific self-monitoring blood glucose devices market is expected to expand at a CAGR of 6.34% during the 2019-2024 period, owing to technological breakthroughs, rising obesity, and the increasing prevalence of diabetes.
Product Segment Insights:
The testing strips segment is expected to hold the highest market share (81.64%) in 2019. Owing to the development of innovative testing strips, and a massive increase in the incidence of diabetes, this segment is expected to witness a high CAGR of 6.94% during the forecast period. The glucometers segment is expected to remain steady while generating 12% of the revenue in the Asia-Pacific market in 2019. Factors like the advantages of glucometers over regular monitoring methodologies and the production of a wide range of devices will drive this segment. However, variations in results due to external and physiological factors will lead to a comparatively low CAGR (4.95%) during the 2019-2024 period.
End User Segment Insights:
The shift of medical services to decentralized surroundings like patients’ homes and the development of portable and user-friendly blood glucose monitoring devices will enable the home settings segment to expand at a CAGR of 6.82% during the 2019-2024 period. The hospitals sector will generate almost 7% of the total market revenue by 2019, and is anticipated to expand at a CAGR of 4.78% during the forecast period.
Country-wise Insights:
China and India account for half of the total diabetic population in the Asia-Pacific region. Advanced medical facilities, awareness programs, and cost-effective treatments to tackle diabetes will transform this region into the fastest-growing SMBG devices market in the world. China is expected to expand at a CAGR of 6.62% during the forecast period, while healthcare initiatives and government programs in India will enable the market in the country to expand at a CAGR of 6.46%.
Companies covered:
• Wockhardt
• Roche Holding
• Abbott Laboratories
• i-SENS
• Terumo Medical
Chapter 1. Executive summary
1.1. Market scope and segmentation
1.2. Key questions answered in this study
1.3. Executive summary
Chapter 2: Asia-Pacific self-monitoring blood glucose devices market – overview
2.1. Market definitions
2.2. Market overview
- Historical market revenue (USD Bn)
- Forecasted market revenue (USD Bn)
- Country-wise market revenue (USD Bn)
2.3. Market trends
2.4. Market drivers
2.5. Market challenges
2.6. Value chain analysis
2.7. Porter’s five forces analysis
Chapter 3: Asia-Pacific self-monitoring blood glucose devices market – based on products
3.1. Testing strips
- Market overview
- Forecasted market segment revenue (USD Bn)
3.2. Glucometers
- Market overview
- Forecasted market segment revenue (USD Bn)
3.3. ‘Others’
- Market overview
- Forecasted market segment revenue (USD Bn)
Chapter 4: Asia-Pacific self-monitoring blood glucose devices market – based on end users
4.1. Hospitals
- Market overview
- Forecasted market segment revenue (USD Bn)
4.2. Diagnostic centers and clinics
- Market overview
- Forecasted market segment revenue (USD Bn)
4.3. Home settings
- Market overview
- Forecasted market segment revenue (USD Bn)
Chapter 5: India self-monitoring blood glucose devices market
5.1. Overview
- Revenue (USD Bn)
- Forecasted market revenue (USD Bn)
5.2. Trends
5.3. Drivers
5.4. Challenges
5.5. Market observations based on products
- Key market observations
- Forecasted market revenue (USD Bn)
5.6. Market observations based on end users
- Key market observations
- Forecasted market revenue (USD Bn)
Chapter 6: China self-monitoring blood glucose devices market
6.1. Overview
- Revenue (USD Bn)
- Forecasted market revenue (USD Bn)
6.2. Trends
6.3. Drivers
6.4. Challenges
6.5. Market observations based on products
- Key market observations
- Forecasted market revenue (USD Bn)
6.6. Market observations based on end users
- Key market observations
- Forecasted market revenue (USD Bn)
Chapter 7: Australia and New Zealand self-monitoring blood glucose devices market
7.1. Overview
- Revenue (USD Bn)
- Forecasted market revenue (USD Bn)
7.2. Trends
7.3. Drivers
7.4. Challenges
7.5. Market observations based on products
- Key market observations
- Forecasted market revenue (USD Bn)
7.6. Market observations based on end-users
- Key market observations
- Forecasted market revenue (USD Bn)
Chapter 8: Rest of Asia-Pacific self-monitoring blood glucose devices market
8.1. Overview
- Revenue (USD Bn)
- Forecasted market revenue (USD Bn)
8.2. Trends
8.3. Drivers
8.4. Challenges
8.5. Market observations based on products
- Key market observations
- Forecasted market revenue (USD Bn)
8.6. Market observations based on end-users
- Key market observations
- Forecasted market revenue (USD Bn)
Chapter 9: Competitive landscape
9.1. Wockhardt*
- Company snapshot
- Products
- Strategic initiatives
- Countries present
- Key people
9.2. Roche Holding
9.3. Abbott Laboratories
9.4. i-SENS
9.5. Terumo Medical
(*) The coverage approach remains the same for all companies
Chapter 10: Conclusion
10.1. PESTEL analysis
10.2. Impact assessment
10.3. Future outlook
Chapter 11: Appendix
11.1. List of tables
11.2. Assumptions
11.3. Research methodology
11.4. About Research on Global Markets
11.5. Disclaimer
The Asia-Pacific self-monitoring blood glucose devices market is expected to expand at a CAGR of 6.34% during the 2019-2024 period, owing to technological breakthroughs, rising obesity, and the increasing prevalence of diabetes.
Product Segment Insights:
The testing strips segment is expected to hold the highest market share (81.64%) in 2019. Owing to the development of innovative testing strips, and a massive increase in the incidence of diabetes, this segment is expected to witness a high CAGR of 6.94% during the forecast period. The glucometers segment is expected to remain steady while generating 12% of the revenue in the Asia-Pacific market in 2019. Factors like the advantages of glucometers over regular monitoring methodologies and the production of a wide range of devices will drive this segment. However, variations in results due to external and physiological factors will lead to a comparatively low CAGR (4.95%) during the 2019-2024 period.
End User Segment Insights:
The shift of medical services to decentralized surroundings like patients’ homes and the development of portable and user-friendly blood glucose monitoring devices will enable the home settings segment to expand at a CAGR of 6.82% during the 2019-2024 period. The hospitals sector will generate almost 7% of the total market revenue by 2019, and is anticipated to expand at a CAGR of 4.78% during the forecast period.
Country-wise Insights:
China and India account for half of the total diabetic population in the Asia-Pacific region. Advanced medical facilities, awareness programs, and cost-effective treatments to tackle diabetes will transform this region into the fastest-growing SMBG devices market in the world. China is expected to expand at a CAGR of 6.62% during the forecast period, while healthcare initiatives and government programs in India will enable the market in the country to expand at a CAGR of 6.46%.
Companies covered:
• Wockhardt
• Roche Holding
• Abbott Laboratories
• i-SENS
• Terumo Medical
